Symptoma

Opioid Withdrawal

Prolonged use of opioid analgesics induces pharmacodynamic tolerance, physical and psychological addiction. Cessation or reduction of opioid administration thus leads to opioid withdrawal, a condition associated with agitation, anxiety and autonomic nervous system disorders.

OW occurs in two stages. Initially, psychiatric symptoms predominate and patients show agitation, anxiety, loss of appetite and insomnia [4]. An increased sympathetic tone adds to this condition, worsens overall weakness, irritability and restlessness. Additional symptoms may partially be ascribed to imbalances of parasympathetic and sympathetic autonomous functions, partially to central nervous system arousal. Mydriasis as well as mild tachycardia and hypertension are characteristic findings. Gastrointestinal symptoms include abdominal pain, nausea, vomiting and diarrhea. Although hypothermia is less commonly detected, patients tend to feel cold and shiver but sweat nevertheless. They may show tremor and suffer from myalgia and muscle cramps. Lacrimation and mucous membrane secretion may be augmented.

Opioid addiction and OW are generally not diagnosed in otherwise healthy patients. Addiction to other drugs is frequently observed and while the vast majority of OW patients smokes, lesser shares of patients regularly consumes alcohol, pharmaceuticals and illegal drugs. Of note, tobacco consumption may exacerbate OW symptoms and render patients less responsive to therapy. Moreover, OW treatment may be significantly complicated by additional withdrawal syndromes. Psychiatric disorders are also common. Anxiety and panic disorder, depression, personality disorder and stress are frequent comorbidities [5]. It is not yet completely understood why prevalence rates of mental disorders are up to three times higher in opioid addicted people than in the general population [6].

Patients suffering from chronic pain and/or using opioids for prolonged periods of time are known to be at higher risk of suicide [7]. It has been suggested that this also applies to patients undergoing OW, although so far no studies have been conducted to this end.

  • Fatigue

    Other symptoms that may be encountered in stage 3 of withdrawal include: • Insomnia • Nausea • Fatigue • Memory loss Unassisted detox carries a certain appeal for many opioid users for several reasons. [matclinics.com]

    Clinical features of opioid withdrawal Opioid withdrawal involves a constellation of symptoms, typically several of the following at the same time: psychological symptoms, such as dysphoria, cravings, insomnia and fatigue flu-like physical symptoms, such [porticonetwork.ca]

    These items produce scores for subscales measuring six distinct affective states (score ranges in parentheses): Tension (0–36), Anger (0–48), Depression (0–60), Vigour (0–32), Fatigue (0–28), and Confusion (0–28). [ncbi.nlm.nih.gov]

    You’ve made it through the most intense withdrawal symptoms, but you’ll probably still experience stomach cramping, minor aches, shivers, and fatigue. [therecoveryvillage.com]

    The signs and symptoms of Opiate Withdrawal can range from mild to severe and may include: Early symptoms: Depression and anxiety Agitation Muscle pain and aches Insomnia Runny nose and teary eyes Hot and cold sweats Yawning Low energy and fatigue Late [dovemed.com]

  • Excessive Daytime Sleepiness

    We present a 30-year-old woman with excessive daytime sleepiness and sleep-disordered breathing for the past 4 years. [ncbi.nlm.nih.gov]

  • Nausea

    Administration of fast-release oxycodone (Oxinome ) at a dose of 10 mg immediately improved his nausea. There have been no previous reports of nausea as the sole symptom of opioid withdrawal. [ncbi.nlm.nih.gov]

    Other symptoms that may be encountered in stage 3 of withdrawal include: • Insomnia • Nausea • Fatigue • Memory loss Unassisted detox carries a certain appeal for many opioid users for several reasons. [matclinics.com]

    Gastrointestinal symptoms include abdominal pain, nausea, vomiting and diarrhea. Although hypothermia is less commonly detected, patients tend to feel cold and shiver but sweat nevertheless. [symptoma.com]

  • Abdominal Pain

    People going through this first step to recovery experience side effects like: Vomiting Diarrhea Severe nausea Abdominal pain Fever Tremors Hallucinations This stage lasts about five days, peaking at the three-day mark. [ashleytreatment.org]

    Gastrointestinal symptoms include abdominal pain, nausea, vomiting and diarrhea. Although hypothermia is less commonly detected, patients tend to feel cold and shiver but sweat nevertheless. [symptoma.com]

    “There is a perception that there is a lot of medicine that is really effective at combating withdrawal symptoms, which are diarrhea, abdominal pain, sweatiness, agitation, and anxiety, but there is not a lot that we can do,” explains Darin Neven, MD, [ahcmedia.com]

    Story highlights Opioid users report weaning off opiates using kratom Kratom is found on the poorly regulated supplements market (CNN) Multiple surgeries couldn't help Lisa Vinson with the chronic abdominal pain stemming from endometriosis, a condition [cnn.com]

  • Arthralgia

    Such symptoms are dysphoria, restlessness, rhinorrhea, lacrimation, myalgias, arthralgias, nausea, vomiting, abdominal cramps, diarrhea, yawning, increased flatulence and piloerection. [bmcpsychiatry.biomedcentral.com]

  • Muscle Twitch

    Grade 0: craving, anxiety, drug-seeking behavior Grade 1: yawning, sweating, lacrimation, rhinorrhea Grade 2: mydriasis, gooseflesh, muscle twitching, anorexia Grade 3: Insomnia, increased pulse, respiratory rate and blood pressure, abdominal cramps, [behavenet.com]

  • Suggestibility

    Within one year, an increase in the number of mentions on Drugbuyers.com, a Web site that facilitates the online purchase of opioid analgesics, suggested that members began managing opioid withdrawal with Kratom. [ncbi.nlm.nih.gov]

  • Facial Pain

    Medical history was complicated by chronic osteomyelitis, periorbital abscess, and chronic facial pain requiring methadone for pain control for the last 4 years. [ncbi.nlm.nih.gov]

  • Altered Mental Status

    A 25-year-old man developed agitation and altered mental status after receipt of XRNTX at the conclusion of a twelve-day detoxification program during which he continued surreptitious use of heroin. [ncbi.nlm.nih.gov]

The patient's medical history is of utmost importance for diagnosis of OW. For instance, recent changes in long-term opioid therapies for chronic pain may trigger OW and patients may readily report this upon inquiry. However, addiction to non-prescribed and illegal opioid drugs may be concealed. Also, patients may not associate flu-like symptoms to drug addiction and withdrawal and need to be questioned in this regard.

The American Psychiatric Association has defined clear criteria for diagnosis of OW [8]. As has been mentioned above, cessation or reduction of high-dose, prolonged opioid therapy induces OW and is therefore mandatory for its diagnosis. Alternatively, effects of a continued opioid therapy may have been drastically decreased by administration of opioid antagonists like naloxone or naltroxene. There needs to be a temporal relation between these events and onset of symptoms characteristic for OW. At least three of the following symptoms should be observed:

OW symptoms are unspecific. Thus, a thorough clinical examination, laboratory analyses of blood and urine samples should be performed. With regard to blood samples, establishment complete hemogram and blood chemistry are recommended. Diagnosis of OW also requires ruling out addiction and withdrawal from other drugs, psychological disorders, intrinsic diseases of the autonomic nervous system and other conditions possibly indicated by the results of laboratory test.

OW is not a life-threatening condition, but symptoms may be significantly alleviated if patients are detoxified in a controlled manner. Hospitalization may be necessary if psychiatric disorders or other comorbidities indicate continuous monitoring or if the patient's social environment constitutes a strong risk factor for relapses. Otherwise, an outpatient therapy may be sufficient.

Methadone, a full μ opioid receptor agonist, and buprenorphine, partial agonist at μ receptors are most frequently applied for opioid detoxification [9]. Slow release forms of other opioids as well as alpha-2 agonists may also be administered. Opioid detoxification with other opioids is based on cross-tolerance, i.e., they are less harmful than the addictive drug but nevertheless satisfy the body's need for opioids. They need to be tapered off slowly. Centrally acting sympathomimetics like lofexidine and clonidine mediate an overall reduction of the sympathetic tone which is why OW patients benefit from these compounds. They are particularly helpful to reduce symptoms that may be ascribed to an increased sympathetic tone. Withdrawal may occur and resolve earlier in patients treated with alpha-2 agonists, but the overall success of therapy based opioid substitution or antisympathotonic drugs is presumably very similar [10]. Side effects may interfere with therapeutic compliance and should be registered accordingly.

Of note, rapid detoxification may be achieved with opioid receptor antagonists naloxone and naltroxene. They fully block μ opioid receptors and therefore provide little relieve from OW symptoms. Therapeutic compliance is very low, which is why this approach should only be considered - if at all - when continuous monitoring can be guaranteed. Nevertheless, the risk of relapse is considered high [9]. Some studies recommend use of opioid receptor antagonists in motivated patients [11].

It is strongly recommended to supplement pharmacological detoxification with psychotherapy and possibly participation in a support group [12]. With regards to the former, distinct approaches promise similar results and patients may benefit from behavioral counseling, structured counseling as well as from family therapy. All have been shown to significantly improve the overall success of OW treatment and to reduce relapse rates [13].

OW is a painful yet not life-threatening process. Severity largely depends on the specific addictive drug and on duration of opioid use. Appropriate treatment may significantly relieve OW symptoms, but the risk of relapses is high.

Both legal and illegal drugs pertaining to the class of opioids may cause addiction and OW upon cessation or reduction of drug application.

In this context, treatment of chronic pain poses a major challenge: Prolonged administration of opioids induces drug tolerance and leads to addiction, but dose reduction causes insufficient analgesia, particularly due to tolerance induction. According to retrospective studies, approximately one out of six patients receiving opioids for chronic pain develops opioid addiction [1]. Opioids generally used for therapy of OW may serve as an alternative treatment of chronic pain [2].

No other opioid causes addiction as fast as heroin. Because heroin is an illegal drug, the inability to procure supplies - and single doses will have to be increased to compensate for drug tolerance - may have the patient suffering from severe OW without consulting health care givers.

According to statistics, opioid abuse is more common among men than it is among women. This particularly applies to use of heroin, which has a male-to-female ratio of three to one. Differences are less pronounced when considering legal opioids prescribed for pain and cough therapy.

Chronic pain is the main reason for prolonged use of opioid analgesics. Its incidence increases with age and thus, opioid addiction and OW upon dose reduction is more frequently seen in the elderly. In contrast, heroin addiction is typically encountered in adolescents and young adults. Early exposure to other legal and illegal drugs often precedes heroin use.

Opioids act on μ, κ, δ and ε receptors that are located in the central nervous system and in the gastrointestinal tract. Their physiological agonists are endorphins and enkephalins. Here, opioids mediate different effects:

  • Opioid binding to μ receptors alters cortical pain perception. Other unpleasant sensations like cold and hunger will be subdued. The vomiting center will be stimulated at low doses, but inhibited upon application of higher amounts of opioids. Also, μ receptor activation leads to respiratory depression, alleviation of cough and intestinal paralysis. μ receptors furthermore mediate euphoria, which is the main reason why opioids induce psychological addiction.
  • κ receptor activation inhibits spinal pain conduction and thus adds to the analgetic effect of opioids.
  • δ receptors presumably contribute to analgesia and respiratory depression.

Additionally, opioids cause imbalances of the autonomic nervous system by decreasing the overall sympathetic tone.

Tolerance to opioids is mainly pharmacodynamic and is caused by down-regulation of μ receptors and a regulatory increase of the sympathetic tone. These long-term effects account for the fact that a sudden cessation of opioid therapy results in dysphoria and autonomic nervous system disorders. In case of opioid analgesics and antitussives, such symptoms of OW may manifest after ending year-long therapies. Heroin, in contrast, triggers a very strong sense of euphoria and thus immediately causes psychological addiction.

Morphine and heroin mediate their effects mainly by binding to μ receptors. Because activation of this receptor triggers euphoria, administration of these compounds is associated with a high risk of addiction. Reduction of doses therefore evokes symptoms of OW. Partial μ and κ receptor agonists like buprenorphine are less potent analgesics but also bear lower risks of addiction and subsequent OW [3].

When considering opioid treatment for a patient suffering from chronic pain or comparable conditions that require strong analgesics or antitussives, benefits and possible side effects should be assessed. Moreover, patients should be advised to strictly follow treatment recommendations, to not increase single doses, augment application frequency or prolong the overall duration of therapy.

Patients should know about the risk of addiction and withdrawal. If treated for OW, they should be able to recognize early symptoms of relapses.

Opioids should be stored safe from unauthorized access. This applies to hospitals and medical practices as well as patients' homes.

Papaver somniferum, colloquially called opium poppy, is a Mediterranean plant whose sap contains pharmacologically active compounds such as morphine and codeine. Both are opiates, i.e., natural compounds. In contrast, semi-synthetic and synthetic drugs like heroin, hydromorphone, hydrocodone as well as fentanyl and methadone, respectively, are rather referred to as opioids. In this article, the term opioid will be used to refer to both classes of drugs.

Opioids are generally prescribed to treat moderate to severe pain and cough. They mainly act on opioid receptors in the central nervous system, but also mediate clinically less important peripheral effects. Unfortunately, drug tolerance is a problem often encountered in patients receiving prolonged opioid treatment. Furthermore, long-term use of opioids induces physical and psychological addiction, developments not independent of drug tolerance. Both contribute to symptoms associated with opioid withdrawal (OW). Patients who discontinue or strongly reduce opioid administration after long periods of regular use will experience psychiatric symptoms, mainly agitation, anxiety and sleep disturbances, and autonomic nervous system disorders.

OW symptoms may be reduced by replacing the addictive drug with methadone or buprenorphine, both opioids themselves, and requires tapering off these substitution treatments. Psychotherapy and support groups may significantly contribute to the success of the therapy.

Most opioids are strong analgesics or antitussives. Also, illegal drugs like heroin pertain to that class of compounds.

Prolonged intake of moderate to high doses of opioids causes a phenomenon called drug tolerance, i.e., the body adjusts to regular doses of these compounds. However, this body is unable to suddenly undo all these changes if opioid administration is ceased or strongly reduced. The respective patient is physically addicted.

Additionally, opioids mediate a sensation of euphoria. With regards to heroin, this euphoria is also referred to as "kick". This pleasant feeling causes psychological addiction.

If the demands for opioids cannot be fulfilled, the patient will likely experience opioid withdrawal (OW).

Causes

Prolonged opioid treatment may be required in patients suffering from chronic pain. Here, the possible side effects of opioid addiction and OW upon cessation of therapy are largely outweighed by the achieved analgesia. Nevertheless, withdrawal becomes much more bearable with appropriate treatment and should therefore receive medical attention.

The inability to procure supplies leaves those patients addicted to non-prescribed or illegal drugs with OW.

Symptoms

Diagnosis

The patient's medical history is of utmost importance for OW diagnosis. A recent change of therapeutic schemes, a major reduction of opioid doses or prescription of an antagonist prompt suspicion for OW. Thorough clinical examination and laboratory tests will be conducted to detect OW-related symptoms and to rule out other pathological conditions that may account for them.

Treatment

There are two distinct therapeutic approaches to OW. One the one hand, the addictive drug may be replaced with other, less harmful opioids that are subsequently tapered off. On the other hand, symptoms may be alleviated by application of non-opioid drugs. It is strongly recommended to supplement drug therapy with psychotherapy and participation in a support group.

  1. Højsted J, Nielsen PR, Guldstrand SK, Frich L, Sjogren P. Classification and identification of opioid addiction in chronic pain patients. Eur J Pain. 2010; 14(10):1014-1020.
  2. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013; 32(1):68-78.
  3. Zuurmond WW, Meert TF, Noorduin H. Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg. 2002; 53(3):193-201.
  4. Kanof PD, Aronson MJ, Ness R. Organic mood syndrome associated with detoxification from methadone maintenance. Am J Psychiatry. 1993; 150(3):423-428.
  5. Lai HM, Huang QR. Comorbidity of mental disorders and alcohol- and drug-use disorders: analysis of New South Wales inpatient data. Drug Alcohol Rev. 2009; 28(3):235-242.
  6. Goldner EM, Lusted A, Roerecke M, Rehm J, Fischer B. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav. 2014; 39(3):520-531.
  7. Kuramoto SJ, Chilcoat HD, Ko J, Martins SS. Suicidal ideation and suicide attempt across stages of nonmedical prescription opioid use and presence of prescription opioid disorders among U.S. adults. J Stud Alcohol Drugs. 2012; 73(2):178-184.
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. In: American Psychiatric Association, ed. Vol 5. Arlington; 2013.
  9. Diaper AM, Law FD, Melichar JK. Pharmacological strategies for detoxification. Br J Clin Pharmacol. 2014; 77(2):302-314.
  10. Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2004; (4):CD002024.
  11. Kunoe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2009; 194(6):541-546.
  12. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005; 62(10):1157-1164.
  13. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011; (9):CD005031.